Compare Recursion Pharmaceuticals Inc (RXRX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Teucrium Wheat Fund trades at $24.01. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | WEAT | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $26.00 |
52-Week Low | $2.84 | $19.88 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
WEAT, the Teucrium Wheat Fund, trades at $23.91, up 0.8% on the day, with a neutral technical signal overall. Recent performance shows strength, gaining 9.9% over the past month and 25% year-to-date as of July 21, 2026 (Zacks Investment Research). Key support and resistance cluster around $24, while oscillators like the relative strength index indicate neutral momentum. The USDA's reduced wheat production outlook for 2026 to 1.56 billion bushels, below analyst expectations (WSJ, May 12, 2026), underscores supply-side influences.
Outlook remains tied to agricultural commodity cycles; inflation trends and crop forecasts drive volatility. Risks include weather disruptions and global demand shifts, but current sentiment is balanced with potential for further gains if supply constraints persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
